Who are the Top 5 Fortune 500 Pharma companies? (2019)
We filtered Fortune’s 2019 ‘World’s Most Admired Companies‘ list, down to find the top 5 Fortune 500 pharma companies of the year.
Fortune’s data findings of the world’s most admired companies from the pharmaceutical industry in the USA, reveals that Johnson & Johnson holds the title again in 2019 – for the sixth year running!
World’s Most Admired Fortune 500 pharma companies 2019
The Fortune 500 ranking is based on total revenues of companies for their 2018 fiscal year. In order to be included in the reputable Fortune 500 list, companies must have filed their taxes with a U.S. governing body. In addition for the World’s Most Admired Companies list, Fortune surveys industry professionals who vote for the companies they admired most.
1.Johnson & Johnson
J&J‘s 2018 net revenue rose by 6.7% YoY from $76.5 billion in 2017 to a whopping $81.6 billion.
Johnson & Johnson Inc is one of the most valuable medical devices and pharmaceutical conglomerates in the world – with an estimated net worth of $360 billion.
The corporation has 250+ subsidiaries and its products are sold in more than 175 countries.
Merck & Co., Inc comes second in the admired Fortune 500 pharma companies chart, with a 2018 net revenue of $42.29 billion dollars.
The company made some significant acquisitions in 2018/19 including cancer drug company, Viralytics for $394 million, Immune Design Corp for nearly $300 million and oncology specialists Peloton Therapeutics for approx. $2.2 billion.
California headquartered Amgen Inc. claims the third place with a net revenue of $23,75 billion in the last year.
The biopharmaceutical company’s best selling product lines in 2018 were Neulasta, an immunostimulator for patients undergoing chemotherapy and Enbrel, used to treat rheumatoid arthritis and other autoimmune diseases.
Headquartered in New York, Bristol-Myers Squibb has placed fourth in the list with $22.56 billion net revenue in 2018. An 8.59% increase from 2017. In January 2019, the prescription pharmaceuticals and biologics manufacturer announced it would acquire Celgene for $74 billion ($95 bill. including debt) – the biggest pharma acquisition to date.
New York based Pfizer declared $53.64 billion in revenue in 2018, and its Fortune industry ranking went up from 10 to 7 as an admired company.
In May 2019 Pfizer confirmed it would acquire Therachon for $810 million to boost their rare disease pipeline. Pfizer says their renewed purpose is to find “Breakthroughs that change patients” lives. With a 90,000+ strong workforce, Pfizer is well placed to achieve these goals.